The Center for Comprehensive Care and Diagnosis of Inherited Blood Disorders (CIBD) in Orange, CA, has been designated a Leading Practice Site as part of the 340B Peer-to-Peer Program.
Established in 2011 by the American Pharmacists Association and the Health Resources and Services Administration (HRSA), the peer-to-peer initiative is designed to spotlight high-performing entities covered under the 340B Program. The 340B Program requires drug manufacturers to provide outpatient drugs to eligible healthcare organizations/covered entities at significantly reduced prices. Several federally funded hemophilia treatment centers (HTCs), including CIBD, are 340B entities.
According to HRSA, Leading Practice Sites such as CIBD provide practical examples of excellence in program integrity, demonstrate continuous quality improvement and compliance with program requirements, while also serving as resources for other 340B entities. Staff from these high-performing sites, along with other 340B subject matter experts, exhibit best practices and policy knowledge to help elevate all 340B stakeholders and promote integrity within the 340B Program.
CIBD is a nonprofit, community-based clinic specializing in all blood disorders. As a federally funded HTC, CIBD owns and operates an in-house pharmacy in which home delivery and services are available. CIBD also participates with the US Department of Health and Human Services (DHSS) in the Patient Safety and Clinical Pharmacy Service Collaborative to improve the safety of patient pharmacy services.
Learn more about 340B Peer-to-Peer Program at the HRSA website.
